Skip to main content
Clinical Trials/NCT02744911
NCT02744911
Completed
Not Applicable

Development of a Telehealth Platform for Treatment With the SpeechVive Device

SpeechVive, Inc2 sites in 1 country143 target enrollmentJanuary 26, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Parkinson Disease
Sponsor
SpeechVive, Inc
Enrollment
143
Locations
2
Primary Endpoint
Change in Caregiver Quality of Life
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

Telehealth, increasingly recognized in the neurology field as a solution to access issues for people with Parkinson's disease, improves access to speech therapy, particularly those living in rural areas or with travel barriers. The SpeechVive device, developed by SpeechVive, Inc., is a treatment solution that is easy to use and effective. In an NIH funded study, the SpeechVive device improved communication in 90% of individuals with PD by improving volume, articulation, and speech rate. The investigators propose to eliminate the one drawback of the SpeechVive device, namely that it currently must be programmed by a speech-language pathologist for each patient in person. The overall goal of this project is to develop a telehealth platform for the SpeechVive device that will enable video conferencing for treatment and remote programming of the SpeechVive device for each patient. Once the platform has been developed, the investigators will conduct a study to examine effectiveness and the patient and caregiver satisfaction with telepractice using the SpeechVive device.

Registry
clinicaltrials.gov
Start Date
January 26, 2018
End Date
June 15, 2019
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
SpeechVive, Inc
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of Parkinson's disease
  • Difficulty communicating
  • Is currently being seen, or agrees to be seen, by a speech pathologist who fits the SpeechVive device and also has agreed to participate in the study
  • Has a regular caregiver living with him/her

Exclusion Criteria

  • Neurological diagnoses (except Parkinson's disease)
  • Bilateral hearing aids (since one free ear is required for use of the SpeechVive device)

Outcomes

Primary Outcomes

Change in Caregiver Quality of Life

Time Frame: Change from baseline after 6 months of treatment

Scale of Quality of Life of Care-givers

Depression: Caregiver Geriatric Depression Scale

Time Frame: Change from baseline after 6 months of treatment

Geriatric Depression Scale

Change in Patient with PD Ratings of Communication Competence

Time Frame: Change from baseline after 6 months of treatment

Communicative Participation Item Bank-Short Form

Change in Patient with PD quality of life

Time Frame: Change from baseline after 6 months of treatment

Parkinson's Disease Questionnaire-39

Attractiveness of the telehealth platform.

Time Frame: At monthly intervals during the study period (6 months for each patient)

Survey requesting SLP data regarding patients seen during the study period and adoption of the telepractice model by patients

Travel cost burden - in-person group

Time Frame: At monthly intervals during the study period (6 months for each patient)

Survey requesting Patient/caregiver travel distances and durations

Impact of treatment on time - telemedicine group

Time Frame: At monthly intervals during the study period (6 months for each patient)

Survey requesting Patient and caregiver reports of time spent before and after sessions preparing and setting up equipment and clearing equipment

Treatment adherence

Time Frame: At monthly intervals during the study period (6 months for each patient)

Usage data from the SpeechVive and patient attendance at treatment sessions

Change in Vocal intensity level

Time Frame: Change from baseline after 6 months of treatment

Sound pressure level from speech samples with and without the device in place

Change in Patient with PD Depression Level

Time Frame: Change from baseline after 6 months of treatment

Geriatric Depression Scale Short form

Impact of Life Events for Patient with PD and Caregiver

Time Frame: Change from baseline after 6 months of treatment

Change in Impact of PD on life satisfaction

Change in general self-efficacy

Time Frame: Change from baseline after 6 months of treatment

Self-efficacy for people with disabilities scale

Secondary Outcomes

  • Change in Speech rate(Change from baseline after 6 months of treatment)
  • Change in Apathy(Change in baseline after 6 months of treatment for Patient with PD and Caregiver)
  • Change in Pausing patterns(Change from baseline after 6 months of treatment)
  • Change in Caregiver Burden(Change from baseline after 6 months of treatment)
  • Change in Caregiver Ratings Patient's of Communication Competence(Change in baseline after 6 months of treatment)
  • Change in Patient with PD Participation in Social Activities(Change in baseline after 6 months of treatment)
  • Change in Patient with PD Perceived Autonomy(Change in baseline after 6 months of treatment)
  • Patient with PD satisfaction - telemedicine group(At the end of the study period (after 6 months))
  • Caregiver satisfaction - telemedicine group(At the end of the study period (after 6 months))
  • Patient with PD satisfaction - in person group(At the end of the study period (after 6 months))
  • Caregiver satisfaction - in person group(At the end of the study period (after 6 months))

Study Sites (2)

Loading locations...

Similar Trials